1. Home
  2. GHRS vs TBLD Comparison

GHRS vs TBLD Comparison

Compare GHRS & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • TBLD
  • Stock Information
  • Founded
  • GHRS 2018
  • TBLD 2021
  • Country
  • GHRS Ireland
  • TBLD United States
  • Employees
  • GHRS N/A
  • TBLD N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • TBLD Investment Managers
  • Sector
  • GHRS Health Care
  • TBLD Finance
  • Exchange
  • GHRS Nasdaq
  • TBLD Nasdaq
  • Market Cap
  • GHRS 774.1M
  • TBLD 643.6M
  • IPO Year
  • GHRS 2021
  • TBLD N/A
  • Fundamental
  • Price
  • GHRS $11.94
  • TBLD $20.24
  • Analyst Decision
  • GHRS Strong Buy
  • TBLD
  • Analyst Count
  • GHRS 8
  • TBLD 0
  • Target Price
  • GHRS $30.63
  • TBLD N/A
  • AVG Volume (30 Days)
  • GHRS 190.5K
  • TBLD 78.0K
  • Earning Date
  • GHRS 11-13-2025
  • TBLD 01-01-0001
  • Dividend Yield
  • GHRS N/A
  • TBLD 6.16%
  • EPS Growth
  • GHRS N/A
  • TBLD N/A
  • EPS
  • GHRS N/A
  • TBLD N/A
  • Revenue
  • GHRS N/A
  • TBLD N/A
  • Revenue This Year
  • GHRS N/A
  • TBLD N/A
  • Revenue Next Year
  • GHRS N/A
  • TBLD N/A
  • P/E Ratio
  • GHRS N/A
  • TBLD N/A
  • Revenue Growth
  • GHRS N/A
  • TBLD N/A
  • 52 Week Low
  • GHRS $6.00
  • TBLD $15.80
  • 52 Week High
  • GHRS $20.50
  • TBLD $20.55
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 34.28
  • TBLD 61.82
  • Support Level
  • GHRS $13.71
  • TBLD $19.63
  • Resistance Level
  • GHRS $14.59
  • TBLD $20.10
  • Average True Range (ATR)
  • GHRS 0.76
  • TBLD 0.28
  • MACD
  • GHRS -0.12
  • TBLD 0.01
  • Stochastic Oscillator
  • GHRS 3.99
  • TBLD 81.88

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About TBLD Thornburg Income Builder Opportunities Trust

Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.

Share on Social Networks: